Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Yamanaka
Ryuya
R
Homma
Junpei
J
Sano
Masakazu
M
Tsuchiya
Naoto
N
Yajima
Naoki
N
Shinbo
Yoshikatsu
Y
Hasegawa
Akira
A
Onda
Kiyoshi
K
Tanaka
Ryuichi
R
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010865:Pilot Projects; D011344:Procarbazine / Q000008:administration & dosage; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D011344:Procarbazine; D000069283:Rituximab; D004317:Doxorubicin; C027260:pirarubicin; D008727:Methotrexate